Effect of Sacubitril Valsartan on Glycemic Control and Body Weight in Subjects With Type 2 Diabetes: A Single-center Retrospective Study

DOI
  • Oba-Yamamoto Chiho
    Sapporo Diabetes and Thyroid Clinic
  • Takeuchi Jun
    Sapporo Diabetes and Thyroid Clinic
  • Sasaki Mai
    Department of Medical Management and Informatics, Faculty of Medical Informatics, Hokkaido Information University
  • Uesugi Masato
    Department of Medical Management and Informatics, Faculty of Medical Informatics, Hokkaido Information University
  • Miyoshi Hideaki
    Aoki Internal Medicine Clinic Department of Rheumatology, Endocrinology, and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University

Bibliographic Information

Other Title
  • 2型糖尿病患者に対するサクビトリルバルサルタン投与が血糖値と体重に与えた影響：単施設後方視的検討

Search this article

Description

<p>We retrospectively examined the changes in HbA1c and body weight and analyzed background factors related to changes in HbA1c in patients with type 2 diabetes mellitus who were treated with sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor (ARNI). The angiotensin II receptor blocker (ARB) group was matched to the control group using the propensity score-matching method. After matching, 45 patients in each group were included in the analysis (mean body mass index, 27.6±5.4 kg/m2; systolic blood pressure, 149.1±17.9 mmHg; and HbA1c, 6.9 %±0.7 %). The systolic blood pressure, HbA1c, and body weight were significantly lower in the ARNI group than in the ARB group, and the HbA1c reduction was significantly larger in dipeptidyl peptidase 4 inhibitor (DPP-4i) users than in DPP-4i non-users. A multiple regression analysis showed that the HbA1c change correlated with the pretreatment HbA1c level and weight change (p < 0.01). The increase in the glucagon-like peptide 1 activity and natriuretic peptide by neprilysin inhibition was suggested to be the mechanism underlying the improvement in blood glucose and weight loss. In conclusion, HbA1c reduction due to ARNI treatment was significant in patients with a high pretreatment HbA1c level, weight loss during treatment, and DPP-4i use.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top